GE
VRTX icon

General Electric’s Vertex Pharmaceuticals VRTX Stock Holding History

General Electric’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,289,471
Closed -$111M – 172
2016
Q2 		$111M Buy
1,289,471
+178,519
+16% +$15.4M 0.58% 63
2016
Q1 		$88.3M Buy
+1,110,952
New +$100M 0.45% 66

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

General Electric's VRTX Position: Q3 2016 in Review

General Electric sold out of Vertex Pharmaceuticals (VRTX) in Q3 2016, closing a stake of 1,289,471 shares — an estimated $111M sold.

General Electric first reported a position in VRTX in Q1 2016 and held it in 2 quarters. The position peaked at $111M in Q2 2016. 490 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

  • General Electric reported no remaining Vertex Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • General Electric sold 1,289,471 Vertex Pharmaceuticals shares in Q3 2016, an estimated $111M.
  • General Electric first reported a position in Vertex Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • General Electric's Vertex Pharmaceuticals position peaked at $111M in Q2 2016.
  • 490 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on General Electric's 13F filing for Q3 2016, filed 10 Nov 2016.